Statins, breast cancer, and an invisible switch?

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 5, 2008, Pages 1026-1027

  Byers, Tim ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; FLUINDOSTATIN; HISTONE DEACETYLASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PROGESTERONE RECEPTOR; SIMVASTATIN;

BREAST CANCER; CANCER PATIENT; CANCER PREVENTION; CANCER RISK; EDITORIAL; HUMAN; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; BREAST TUMOR; DRUG EFFECT; FEMALE; NOTE; PATHOLOGY; TUMOR RECURRENCE;

BREAST NEOPLASMS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 52649121909     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0290     Document Type: Editorial

References (19)

1. Kumar AS, Benz CC, Shim V, Minami CA, Moore DH, Esserman LJ. Estrogen receptor negative breast cancer is less likely to arise among lipophilic statin users, this issue.
2. Kwan ML, Habel LA, Flick ED, Quesenberry CP, Caan B. Postdiagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat. Epub ahead of print 2007.
3. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Stains and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol 2006;24:4808-17.
4. Dale KM, Coleman CI, Henyan NN, White CM. Statins and cancer risk: a meta-analysis. JAMA 2006;295:74-80.
5. Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol 2007;50:409-18.
6. Browning DRL, Martin RM. Statins and risk of cancer: a systematic reviewand meta-analysis. Int J Cancer 2006;120:833-43.
7. Bonavas S, Filioussi K, Tsavaris N, Sitaras NM. Use of statins and breast cancer: a meta-analysis of seven randomized controlled clinical trials and nine observational studies. J Clin Oncol 2005;23:8606-12.
8. Pocobelli G, Newcomb PA, Trentham-Dietz A, Titus-Ernstoff L, Hampton JM, Egan KM. Statin use and risk of breast cancer. Cancer 2008;112:27-33.
9. Boudreau DM, Gardner JS, Malone KE, Heckbert SR, Blough DK, Daling JR. The association between 3-Hydroxyl-3-Methylglutaryl Coenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study. Cancer 2004;100:2308-16.
10. Coogan PF, Rosenberg L, Strom BL. Statin use and the risk of 10 cancers. Epidemiology 2007;18:213-9.
11. Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP, Habel LA. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 2008;17:27-36.
12. Setoguchi S, Glynn RJ, Avorn J, Mogun H, Schneeweiss S. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation 2007;115:27-33.
13. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Serum lipids, lipid-lowering drugs, and the risk of breast cancer. Arch Intern Med 2005;165:2264-71.
14. Cauley JA, McTiernan A, Rodabough RJ, et al. Statin use and breast cancer: prospective results from the Women's Health Initiative. J Natl Cancer Inst 2006;98:700-7.
15. Boudreau DM, Yu O, Miglioretti DL, Buist DSM, Heckbert SR, Daling JR. Statin use and breast cancer risk in a large population-based setting. Cancer Epidemiol Biomarkers Prev 2007;16:416-21.
16. Sassano A, Platanias LC. Statins in tumor suppression. Cancer Lett. Epub ahead of print 2008.
17. Brown AJ. Cholesterol, statins, and cancer. Clin Exp Pharmacol Physiol 2007;34:135-41.
18. Zhou Q, Atadja P, Davidson NE. Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor A (ER) gene expression without loss of DNA hypermethylation. Cancer Biol Ther 2007;6:64-9.
19. Glass AG, Lacey JV, Jr., Carreon JD, Hoover RN. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 2007;99:1152-61.